Amarin | AMRN - Selling And Administration Expenses

Stock Price
15.34
Daily Change
-1.03 -6.29%
Monthly
-1.92%
Yearly
85.36%
Q1 Forecast
14.88

Amarin reported $17.94M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
Amarin USD 17.94M 17.86M Sep/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
BioCryst Pharmaceuticals USD 80.47M 15.39M Dec/2024
DBV Technologies USD 3.63M 3.18M Sep/2025
Esperion Therapeutics USD 39.98M 4.21M Sep/2024
GlaxoSmithKline GBP 2.68B 518M Dec/2025
Halozyme Therapeutics USD 64.64M 27.11M Dec/2025
Heron Therapeutics USD 23.34M 4.18M Sep/2024
Ionis Pharmaceuticals USD 130M 43.43M Dec/2025
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
Novartis USD 3.31B 134M Sep/2025